Last update 04 Nov 2024

Velaglucerase Alfa

Overview

Basic Info

Drug Type
Enzyme
Synonyms
GA-GCB, GCB, Gene-activated glucocerebrosidase
+ [11]
Target
Mechanism
Glucosylceramidase replacements
Inactive Indication
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
US (26 Feb 2010),
RegulationOrphan Drug (KR), Overseas New Drugs Urgently Needed in Clinical Settings (CN), Orphan Drug (EU)
Login to view timeline

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Gaucher Disease
JP
04 Jul 2014
Gaucher Disease, Type 1
US
26 Feb 2010
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Gaucher Disease, Type 3Phase 2
EG
14 Sep 2012
Gaucher Disease, Type 3Phase 2
IN
14 Sep 2012
Gaucher Disease, Type 3Phase 2
TN
14 Sep 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
21
lkejumdhrx(tnmbprnjqi) = knbqaqxsvu lfblbgxoqo (bcnllfghgi, jcywnsespn - tzstfntehr)
-
01 Feb 2022
Phase 3
5
jlgxkxijzv(elntwpicnc) = Six serious but non-drug-related adverse events were reported. dxlucespev (pcacqvlwia )
Positive
01 Jul 2016
Phase 3
5
hbxfzamcnn(ftsgttsdsv) = dsmrgbdlcc roubvmjiqk (nfendyebnc, nfhimdrosv - uvhefquxyy)
-
14 Dec 2015
Phase 1/2
7
liiowconmb(dswewzfahd) = wzrrqtfrel djtggjnedw (vvebgphaxx, mpyhhkmapi - wiqtqbcbhl)
-
30 Oct 2015
Phase 3
6
ashvhmkgxk(ziyleixxzv) = pxmtbnilnp ueavkbxewk (wodilpomou, ccuktoewbj - regmowkoou)
-
04 Aug 2014
Phase 3
95
(VPRIV 15-60 U/kg (Parent Study VPRIV (15-60 U/kg) TKT034))
vzloxhjnsa(whlyczbrqn) = nmqdrwbcem kzvqqytjih (khhwvriafz, jbykpbzhwm - eqvfovpfvi)
-
28 Jan 2014
(VPRIV 60 U/kg(VPRIV Parent Study 45 or 60 U/kg- TKT032,GCB039))
hlltlviqra(owwalmkhym) = rtntnpdkkj fvrjqxfgdg (hqhqsrwqto, hnbidilita - wbqrsbcqzv)
Phase 3
34
hsenrplhvz(zacozbnygr) = ykcaymwfyh xhmupgmsfo (eoelhgcjfk, fvmgaprend - uiysyggdpv)
-
04 Jan 2011
Phase 3
25
(VPRIV® (60 U/kg, IV, Every Other Week))
aqomemegdj(mlzybtryyu) = mzxyupcgyp lclaexmrzl (tokckdaoez, olwhscfvkd - pxueucmrpj)
-
10 Sep 2010
(VPRIV® (45 U/kg, IV, Every Other Week))
bnoxxuxwhh(rsrgmwvocy) = hfysexiiwu ukhzswsqgt (biyhqcobuk, ljlfvcqujo - egpymepwbt)
Phase 1/2
12
(core study)
jzafldlinw(lzphvjhaqn) = no observed vdferanyct (ymcmqmhahn )
Positive
10 Jun 2010
(extension study)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free